The launch of new Peg-Intron anti-HCV therapies failed to compensate for declining overall sales of the company's group of Intron A therapies, the company reported.
Sales of this group of therapies in the second quarter of this year totalled 315 million dollars - a fall of 13% on the same period last year.
Worldwide sales of the Intron A products continued to rise during this quarter - but they slumped in the US market by 32%, achieving total sales of 147 million dollars. American doctors are said to be waiting for approval for longer-acting versions of the drugs.
The international sales rose by 16% to 169 million pounds (241 million dollars), boosted by the European Union's approval in March of Peg-Intron/Rebetol combination therapy for the treatment of chronic HCV.
The company was also hit by quality control difficulties in its manufacturing operations.
Chairman Richard Jay Kogan said: "World-wide pharmaceutical sales for the second quarter included strong demand for a number of the company's newer products."
"We also continue to see good growth in our international markets, driven by higher sales in the allergy/respiratory and anti-infective/anticancer product categories."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com